Kawasaki Disease

Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease

Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

Cardiovascular Status of Children 5 Years After Kawasaki Disease

MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS)

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease

Kawasaki MATCH Trial

European and North Indian Cohort of KaWasaki dIsease

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

Cardiovascular Risk in Children With Chronic Conditions Study

Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease

Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

Non Inferiority KawasakI Trial With Anakinra

The Value of Cardiovascular Imaging in Kawasaki Disease